Effect of MK-2828 on rosuvastatin and furosemide in healthy adults
A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants
This study tests whether MK-2828 changes how healthy adults absorb, process, or clear the commonly used drugs rosuvastatin or furosemide.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 39 (estimated) |
| Ages | 24 Years to 60 Years |
| Sex | All |
| Sponsor | Merck Sharp & Dohme LLC Industry-sponsored |
| Locations | 1 site (Daytona Beach, Florida) |
| Trial ID | NCT07431866 on ClinicalTrials.gov |
What this trial studies
This is a Phase 1 clinical pharmacology study in healthy adult volunteers to characterize potential drug-drug interactions between MK-2828 and either rosuvastatin or furosemide. Participants who meet health and BMI criteria will receive controlled doses of the listed medicines and have blood and urine samples collected over time to measure drug levels and clearance. Safety and tolerability will be monitored throughout the study and participants with significant medical history or malignancy are excluded. The goal is to define any effect MK-2828 has on the pharmacokinetics of these reference drugs to guide later development.
Who should consider this trial
Good fit: Healthy adults with a body mass index between 18 and 32 kg/m² and no significant medical history are the intended participants for this study.
Not a fit: People with active or past major medical conditions (including cancer), or those on chronic statin or diuretic therapy, are unlikely to receive direct benefit from participation.
Why it matters
Potential benefit: If successful, the results could show whether MK-2828 changes blood levels of rosuvastatin or furosemide so clinicians can adjust dosing or monitor patients safely when using MK-2828 in HFpEF.
How similar studies have performed: Pharmacokinetic drug-drug interaction studies are a standard and reliable approach to detect effects on drug levels, but MK-2828 itself is a new investigational agent with limited publicly reported interaction data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases * Has a history of cancer (malignancy)
Where this trial is running
Daytona Beach, Florida
- Fortrea Clinical Research Unit Inc ( Site 0001) — Daytona Beach, Florida, United States (Recruiting)
Study contacts
- Study coordinator: Toll Free Number
- Email: Trialsites@msd.com
- Phone: 1-888-577-8839
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.